Acorda Therapeutics Inc (ACOR): Andrew A. Hindman , Chief Business Dev. Officer of Acorda Therapeutics Inc sold 4,860 shares on May 13, 2016. The Insider selling transaction was reported by the company on May 16, 2016 to the Securities and Exchange Commission. The shares were sold at $26.11 per share for a total value of $126,884.88 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on Apr 21, 2016, Lorin Randall (director) sold 1,488 shares at $28.68 per share price.On Jan 6, 2016, Ian F Smith (director) sold 13,231 shares at $42.05 per share price.Also, On Dec 28, 2015, Jane Wasman (President, Intl and GC) sold 10,751 shares at $43.10 per share price.On Dec 23, 2015, Lauren M Sabella (Chief Commercial Officer) sold 7,113 shares at $42.04 per share price.
Acorda Therapeutics Inc: On Friday, May 13, 2016 heightened volatility was witnessed in Acorda Therapeutics Inc which led to swings in the share price. The shares opened for trading at $26.13 and hit $26.62 on the upside , eventually ending the session at $26.41, with a gain of 0.57% or 0.15 points. The heightened volatility saw the trading volume jump to 5,36,623 shares. The 52-week high of the share price is $43.63 and the company has a market cap of $1,217 M . The 52-week low of the share price is at $24.83.
Company has been under the radar of several Street Analysts.Acorda Therapeutics Inc is Initiated by Goldman to Sell. The Rating was issued on Mar 30, 2016.
Acorda Therapeutics Inc. is a biopharmaceutical company engaged in the identification development and commercialization of therapies that restore neurological function and treat patients with neurological disorders. The Companys markets three United States Food and Drug Administration (FDA)-approved therapies including Ampyra (dalfampridine) Extended Release Tablets 10milligrams a treatment to improve walking in patients with multiple sclerosis (MS). It also markets Zanaflex Capsules and tablets FDA-approved as short-acting drugs for the management of spasticity and Qutenza an FDA-approved dermal patch for the management of neuropathic pain associated with post-herpetic neuralgia also known as post-shingles pain. The Company is also developing a number of clinical and preclinical stage therapies for the treatment of a range of disorders including chronic post-stroke walking deficits (PSWD) Parkinsons disease epilepsy heart failure MS and spinal cord injury.